Resources & Guides
Educational content about GLP-1 medications, pharmacokinetics, and optimizing your treatment journey.
GLP-1 Medication Hubs
Comprehensive guides for each GLP-1 medication—dosing protocols, clinical trial data, microdosing strategies, and our free calculators.
Semaglutide Guide
Ozempic & Wegovy: GLP-1 receptor agonist. ~15% weight loss, 7-day half-life. FDA-approved for diabetes and weight management.
Tirzepatide Guide
Mounjaro & Zepbound: Dual GLP-1/GIP agonist. ~21% weight loss, 5-day half-life. The first dual-agonist approved by FDA.
Retatrutide Guide
Triple GLP-1/GIP/Glucagon agonist. ~24% weight loss in trials, 6-day half-life. Expected FDA approval 2027.
Educational Content
Semaglutide Injection Sites: Where to Inject Ozempic and Wegovy
articleSemaglutide is injected subcutaneously into the abdomen, thigh, or upper arm. Ozempic and Wegovy list the same three sites but are not the same product on paper: different devices, slightly different rotation wording, and one insulin instruction that appears on only one of the two labels.
Mounjaro Injection Sites: Where to Inject, Rotate, and What to Avoid
articleMounjaro's own FDA label approves three subcutaneous injection sites: abdomen, thigh, and back of the upper arm. This guide covers each site, the two Mounjaro device sequences, and how to plan a weekly rotation around a daily insulin schedule.
Retatrutide Injection Sites: Where to Inject and How to Rotate
educationRetatrutide (LY3437943) is injected subcutaneously once weekly into one of three DailyMed-confirmed sites: abdomen, thigh, or upper arm. This guide covers each site, how to rotate with every dose, what the label requires for prep, and which local reactions to watch for.
Zepbound (Tirzepatide) Injection Sites: Where to Inject & Rotate
educationZepbound is FDA-approved for subcutaneous injection in three sites: abdomen, thigh, and back of upper arm. This guide covers each site, how to rotate with every weekly dose, what skin to avoid, and how to track your schedule.